PDSB vs. SELB, INO, LRMR, FULC, VERV, NGNE, SLRN, TBPH, CTNM, and ESPR
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), Larimar Therapeutics (LRMR), Fulcrum Therapeutics (FULC), Verve Therapeutics (VERV), Neurogene (NGNE), Acelyrin (SLRN), Theravance Biopharma (TBPH), Contineum Therapeutics (CTNM), and Esperion Therapeutics (ESPR). These companies are all part of the "medical" sector.
PDS Biotechnology (NASDAQ:PDSB) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
PDS Biotechnology has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 42.0% of Selecta Biosciences shares are owned by institutional investors. 10.0% of PDS Biotechnology shares are owned by company insiders. Comparatively, 31.2% of Selecta Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, PDS Biotechnology had 1 more articles in the media than Selecta Biosciences. MarketBeat recorded 1 mentions for PDS Biotechnology and 0 mentions for Selecta Biosciences. PDS Biotechnology's average media sentiment score of 1.89 beat Selecta Biosciences' score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media.
PDS Biotechnology currently has a consensus target price of $17.33, indicating a potential upside of 481.66%. Selecta Biosciences has a consensus target price of $2.80, indicating a potential upside of ∞. Given Selecta Biosciences' higher possible upside, analysts plainly believe Selecta Biosciences is more favorable than PDS Biotechnology.
PDS Biotechnology has a net margin of 0.00% compared to Selecta Biosciences' net margin of -72.04%. Selecta Biosciences' return on equity of -44.13% beat PDS Biotechnology's return on equity.
Selecta Biosciences has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.
Selecta Biosciences received 271 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 67.42% of users gave PDS Biotechnology an outperform vote while only 57.47% of users gave Selecta Biosciences an outperform vote.
Summary
Selecta Biosciences beats PDS Biotechnology on 9 of the 17 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
